目的 探讨利肺片联合盐酸莫西沙星注射液治疗慢性支气管炎急性加重期患者的临床疗效。方法 共纳入2024年7月—2025年10月于太原市中心医院就诊的慢性支气管炎急性加重患者109例，采用区组随机化法将所有患者分为对照组（54例）和治疗组（55例）。对照组患者静脉滴注盐酸莫西沙星注射液，0.4 g/次加入5%葡萄糖注射液250 mL，1次/d。治疗组在对照组基础上口服利肺片，2片/次，3次/d。两组患者连续给药5 d。比较两组患者临床疗效、临床症状好转时间，治疗前后肺功能指标第1秒末用力呼气量（FEV1）、用力肺活量（FVC）、每分钟最大通气量（MVV）和FEV1/FVC、血清炎症指标白细胞介素-6（IL-6）、IL-8和C反应蛋白（CRP）水平。结果 治疗后，治疗组患者总有效率为94.55%，明显高于对照组的81.48%（P＜0.05）。治疗后，治疗组患者咳嗽、咳痰、喘息、哮鸣音缓解时间显著短于对照组（P＜0.05）。与治疗前相比，两组患者治疗后FEV1、FVC、FEV1/FVC和MVV均明显升高（P＜0.05），同时治疗组肺功能指标均明显高于对照组（P＜0.05）。与治疗前相比，两组患者治疗后血清炎症指标均明显下降（P＜0.05），治疗后，治疗组血清IL-6、IL-8和CRP水平均显著低于对照组（P＜0.05）。结论 利肺片联合盐酸莫西沙星注射液治疗慢性支气管炎急性加重患者的疗效显著提高，能够缩短临床症状好转时间，改善肺功能和炎症指标，安全性高。

Objective To explore the clinical efficacy of Lifei Tablets combined with moxifloxacin hydrochloride injection in the treatment of patients with acute exacerbation of chronic bronchitis. Methods A total of 109 patients with acute exacerbation of chronic bronchitis admitted to Taiyuan Central Hospital from July 2024 to October 2025 were enrolled and divided into control group (54 cases) and treatment group (55 cases) by block randomization method. The control group received intravenous infusion of Moxifloxacin Hydrochloride Injection at a dose of 0.4 g diluted in 250 mL 5% glucose injection, once daily. On the basis of the above regimen, the treatment group was additionally given oral Lifei Tablets, 2 tablets each time, three times a day. Both groups received continuous medication for 5 days. The clinical efficacy and relief time of clinical symptoms were compared between the two groups. Pulmonary function indicators including forced expiratory volume in one second (FEV1), forced vital capacity (FVC), maximal voluntary ventilation (MVV) and FEV1/FVC ratio, as well as serum inflammatory markers interleukin-6 (IL-6), interleukin-8 (IL-8) and C-reactive protein (CRP) were detected before and after treatment. Results After treatment, the total effective rate of the treatment group was 94.55%, which was significantly higher than 81.48% of the control group (P< 0.05). After treatment, the recovery time of cough, expectoration, wheezing and wheezing sounds in treatment group was significantly shorter than that in control group (P < 0.05). Compared with before the treatment, FEV1, FVC, MVV and FEV1/FVC were significantly increased in both groups after treatment (P < 0.05), and these pulmonary function parameters were notably higher in the treatment group (P < 0.05). The serum levels of inflammatory factors were decreased remarkably in both groups after treatment (P < 0.05), while the treatment group presented lower levels of IL-6, IL-8 and CRP than the control group (P < 0.05). Conclusion The combination of Lifei Tablets and moxifloxacin hydrochloride injection can significantly improve the therapeutic effect for patients with acute exacerbation of chronic bronchitis. This regimen shortens the relief time of clinical symptoms, ameliorates pulmonary function and reduces inflammatory responses, with good safety profile.

R974

山西省卫生健康委科研课题（2024010）